Thyroid Lymphoma Workup
- Author: Fernando Cabanillas, MD; Chief Editor: Emmanuel C Besa, MD more...
Once the diagnosis of thyroid non-Hodgkin lymphoma (NHL) is established, the following laboratory studies should be obtained:
Complete blood count (CBC)
Serum lactate dehydrogenase (LDH) level
Serum beta 2 -microglobulin level
Bone marrow aspiration and biopsy
Thyroid function tests
Antithyroglobulin or antimicrosomal antibodies
The serum LDH and beta2 -microglobulin levels are important because of their ability to help predict the prognosis. The CBC and the bone marrow studies are important as part of the staging evaluation. Because of the high incidence of hypothyroidism, it is important to evaluate thyroid function.
Plain Radiography, CT, Gallium Scanning, and PET
It is necessary to perform chest radiography and computed tomography (CT) of the head and neck, the chest, the abdomen, and the pelvis. (See the image below.) These are critical tests for determining the stage or extent of disease.
In cases involving bulky disease, either gallium scanning or positron emission tomography (PET) should be performed. These modalities can be helpful later on in determining whether any residual abnormality seen on radiographic studies after treatment contains active lymphoma or just scar tissue.
In current practice, the diagnosis of thyroid lymphoma can be easily established by means of either fine-needle aspiration (FNA) or core-needle biopsy, thus obviating the extensive surgery usually performed for thyroid carcinoma. With the aid of immunophenotyping, non-Hodgkin lymphoma (NHL) should be readily distinguishable from thyroid carcinoma. Furthermore, the distinction between large-cell lymphoma and follicular center-cell lymphoma can be made on the basis of cytologic and immunophenotyping criteria.
The major histologic types of thyroid NHL are as follows :
Mucosa-associated lymphoid tissue (MALT) lymphoma (MALToma)
Burkitt lymphoma (rare)
In a study from Japan that evaluated 171 patients with primary thyroid lymphoma, the distribution of pathologic diagnoses was as follows :
Diffuse large B-cell lymphoma (DLBCL) - 43%
DLBCL with MALToma - 8%
MALToma - 47%
Other - 2%
Determining the extent of disease in NHL is crucial for helping determine the prognosis and select treatment. In thyroid lymphoma, however, a conceptual problem arises, in that most investigators have tended to believe that only thyroid lymphomas that are in the early Ann Arbor stages (ie, I-II) can be considered as being of primary thyroid origin.
The explanation for this view is that advanced presentations can represent a lymphoma metastasizing to the thyroid rather than a primary thyroid lymphoma. Although primary thyroid lymphomas have metastatic potential and can present in stages III-IV, there is no histologic marker that can be used to separate those that are primary in the thyroid from those that are metastatic to the thyroid; thus, most literature series, by definition, include only stage I-II cases.
For the purposes of prognosis, the aggressive thyroid cell types (most commonly the large-cell NHLs) can be classified on the basis of the International Prognostic Index (IPI). This prognostic system assigns 1 point to each of the following variables:
Age older than 60 years
Performance status greater than 1
Elevated lactic dehydrogenase (LDH) level
Number of extranodal sites greater than 1
Ann Arbor stage III-IV
In a study by Ha et al that tested the ability of the IPI to predict the prognosis for patients with thyroid lymphoma, the 5-year survival rate was 86% for those presenting with an IPI of 0, compared with 50% for those with an IPI greater than 0. . These data included patients treated with radiation therapy alone, patients treated with chemotherapy alone, and patients treated with combined-modality therapy. A 2010 study evaluated prognostic factors in a large population-based study and found that older age, advanced stage, histologic subtype, and lack of radiation/surgical treatment were adverse factors for survival.
Holm LE, Blomgren H, Lowhagen T. Cancer risks in patients with chronic lymphocytic thyroiditis. N Engl J Med. 1985 Mar 7. 312(10):601-4. [Medline].
Isaacson PG. Lymphoma of the thyroid gland. Curr Top Pathol. 1997. 91:1-14. [Medline].
Ansell SM, Grant CS, Habermann TM. Primary thyroid lymphoma. Semin Oncol. 1999 Jun. 26(3):316-23. [Medline].
Peppa M, Nikolopoulos P, Korkolopoulou P, Lapatsanis D, Dimitriadis G, Hadjidakis D, et al. Primary mucosa-associated lymphoid tissue thyroid lymphoma: a rare thyroid neoplasm of extrathyroid origin. Rare Tumors. 2012 Jan 2. 4(1):e2. [Medline]. [Full Text].
Pasieka JL. Anaplastic cancer, lymphoma, and metastases of the thyroid gland. Surg Oncol Clin N Am. 1998 Oct. 7(4):707-20. [Medline].
Tupchong L, Hughes F, Harmer CL. Primary lymphoma of the thyroid: clinical features, prognostic factors, and results of treatment. Int J Radiat Oncol Biol Phys. 1986 Oct. 12(10):1813-21. [Medline].
Graff-Baker A, Sosa JA, Roman SA. Primary thyroid lymphoma: a review of recent developments in diagnosis and histology-driven treatment. Curr Opin Oncol. 2010 Jan. 22(1):17-22. [Medline].
Pappa VI, Hussain HK, Reznek RH, et al. Role of image-guided core-needle biopsy in the management of patients with lymphoma. J Clin Oncol. 1996 Sep. 14(9):2427-30. [Medline].
Ha CS, Shadle KM, Medeiros LJ, et al. Localized non-Hodgkin lymphoma involving the thyroid gland. Cancer. 2001 Feb 15. 91(4):629-35. [Medline].
Watanabe N, Noh JY, Narimatsu H, et al. Clinicopathological features of 171 cases of primary thyroid lymphoma: a long-term study involving 24 553 patients with Hashimoto's disease. Br J Haematol. 2011 Mar 4. [Medline].
International Non-Hodgkin Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin''s lymphoma. The International Non-Hodgkin''s Lymphoma Prognostic Factors Project. N Engl J Med. 1993 Sep 30. 329(14):987-94. [Medline].
Matsuzuka F, Miyauchi A, Katayama S, et al. Clinical aspects of primary thyroid lymphoma: diagnosis and treatment based on our experience of 119 cases. Thyroid. 1993 Summer. 3(2):93-9. [Medline].
Miller TP, Dahlberg S, Cassidy JR, et al. Three cycles of CHOP (CHOP-3) plus radiotherapy (RT) is superior to eight cycles of CHOP (CHOP-8) alone for localized intermediate grade non-Hodgkin's lymphoma (NHL). A Southwest Oncology Group study. Proc Ann Meet Am Soc Clin Oncol. 1996. 15 (A1257):411.
Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood. 2010 Sep 23. 116(12):2040-5. [Medline]. [Full Text].
Rodriguez J, Cabanillas F, McLaughlin P, et al. A proposal for a simple staging system for intermediate grade lymphoma and immunoblastic lymphoma based on the ''tumor score''. Ann Oncol. 1992 Nov. 3(9):711-7. [Medline].
Austin JR, el-Naggar AK, Goepfert H. Thyroid cancers. II. Medullary, anaplastic, lymphoma, sarcoma, squamous cell. Otolaryngol Clin North Am. 1996 Aug. 29(4):611-27. [Medline].
Glick JH, Kim K, Earle J, et al. An ECOG randomized phase III trial of CHOP vs. CHOP + radiotherapy (XRT) for intermediate grade early stage non-Hodgkin's lymphoma (NHL) [abstract]. Proceedings of the American Society of Clinical Oncology. 1995. 14 (A-1221):391.
Laing RW, Hoskin P, Hudson BV, et al. The significance of MALT histology in thyroid lymphoma: a review of patients from the BNLI and Royal Marsden Hospital. Clin Oncol (R Coll Radiol). 1994. 6(5):300-4. [Medline].
Miller TP, Dahlberg S, Cassady JR, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin''s lymphoma. N Engl J Med. 1998 Jul 2. 339(1):21-6. [Medline].
Swan F Jr, Velasquez WS, Tucker S, et al. A new serologic staging system for large-cell lymphomas based on initial beta 2-microglobulin and lactate dehydrogenase levels. J Clin Oncol. 1989 Oct. 7(10):1518-27. [Medline].
Velasquez WS, Jagannath S, Tucker SL, et al. Risk classification as the basis for clinical staging of diffuse large- cell lymphoma derived from 10-year survival data. Blood. 1989 Aug 1. 74(2):551-7. [Medline]. [Full Text].